{"filings":[{"id":94642,"accession_number":"0001104659-26-044890","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Mustang Bio receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 15, 2026 for non-compliance with minimum bid price rule after 30 consecutive business days below $1.00.","Has 180-calendar day grace period until October 12, 2026 to regain compliance by closing at $1.00+ for 10 consecutive business days.","May qualify for second 180-day period if meets Nasdaq continued listing criteria and provides written notice of intent to cure.","Could face delisting if unable to regain compliance; no decision yet on specific actions to remedy deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123499,"accession_number":"0001104659-25-124189","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Mustang Bio terminates CD20 CAR-T license with Fred Hutch, pays $730K to settle $1.4M in payables","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated CD20 CAR-T license with Fred Hutch; agreed to pay $730,000 to settle ~$1.4M in outstanding payables.","Fred Hutch to pay Mustang at least 10% of consideration from any third-party CD20 licensing within three years.","All four proposals passed at Dec 22 annual meeting: directors elected, KPMG ratified, ESPP shares raised to 259,333, EIP to 2,514,666."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140175,"accession_number":"0001104659-25-066520","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mustang Bio gets FDA Orphan Drug Designation for MB-101 CAR T-cell therapy in astrocytomas and glioblastoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug Designation to MB-101 for recurrent diffuse/anaplastic astrocytoma and glioblastoma.","Designation provides tax credits, fee waivers, and potential 7-year market exclusivity upon approval.","Phase 1 trial showed 50% stable disease or better; two complete responses lasting 7.5 and 66+ months.","Preclinical data support combining MB-101 with oncolytic virus MB-108 to improve efficacy.","Company notes development of MB-109 program is contingent on raising additional funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176197,"accession_number":"0001104659-25-020900","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mustang Bio regains compliance with Nasdaq minimum stockholders' equity requirement; listing matters closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Feb 26, 2025 notice from Nasdaq confirming compliance with minimum stockholders' equity rule (Rule 5550(b)(1)).","Previously regained compliance with minimum bid price rule; now meets all Nasdaq Capital Market listing criteria.","Subject to Panel Monitor for one year through Feb 26, 2026; non-compliance triggers hearing without plan submission.","Press release issued March 5, 2025 announcing the compliance determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176196,"accession_number":"0001104659-25-018299","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Mustang Bio sells fixed assets to AbbVie for $1M, exits Worcester facility","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of furniture, fixtures, equipment to AbbVie for $1.0M; lease terminated.","Exits manufacturing facility in Worcester, MA; corporate HQ moved to Waltham, MA.","Expects ~$2.0M cash savings over 24 months from lease termination.","Plans to rely on academic partners and contract manufacturers for clinical trials.","Aims to initiate MB-109 (HSV-1 oncolytic virus + CAR-T) trial for GBM in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176195,"accession_number":"0001104659-25-016145","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mustang Bio shareholders approve issuance of up to 5.48M shares underlying warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Written consent signed by holders of ~56% of voting power authorizing warrant share issuance under Nasdaq Rule 5635(d).","Issuance covers up to 5,475,082 shares of common stock underlying warrants issued to H.C. Wainwright & Co. and accredited investors.","Consent holders: 131,052 common shares and 250,000 Class A Preferred shares (each with ~8.4 votes).","Definitive information statement on Schedule 14C to be filed and sent to stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176194,"accession_number":"0001104659-25-013029","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Mustang Bio sells FF&E for $1M, terminates Worcester lease; expects ~$2M savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold FF&E to AbbVie for $1.0M cash; lease termination expected to save ~$2.0M in lease obligations.","Lease base term (ending Oct 2026) terminated early; company to vacate 377 Plantation St within ~20 business days.","Waived lease extension options; no further rent or operating expenses after Early Termination Date.","Escrow agent holds purchase price pending inspection of FF&E condition; agreement provides for price adjustment if FF&E insufficient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176193,"accession_number":"0001104659-25-011517","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Mustang Bio closes $8M public offering, regains Nasdaq minimum bid compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced $8M offering of 2.66M shares (or equivalents) and Series C-1/C-2 warrants at $3.01 per unit; closed Feb 10, 2025.","Net proceeds ~$6.9M; warrants exercisable upon stockholder approval at $3.01/share.","Received Nasdaq notice of compliance with Bid Price Rule (minimum bid $1.00) after 1-for-50 reverse stock split on Jan 15.","Company believes it now meets Nasdaq equity rule ($2.5M minimum) following offering; awaiting formal determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176192,"accession_number":"0001104659-25-004565","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Mustang Bio effects 1-for-50 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Outstanding shares reduced from ~64.8M to ~1.3M; split effective Jan 15, 2025.","Trading on split-adjusted basis under symbol MBIO begins Jan 16, 2025.","Reverse split intended to meet Nasdaq's $1.00 minimum bid price requirement.","No fractional shares issued; cash payment in lieu for fractional entitlements.","New CUSIP 62818Q302; board set final ratio on Jan 6, 2025 per prior stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176191,"accession_number":"0001104659-25-002599","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mustang Bio stockholders authorize issuance of up to 34.8M shares underlying warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders representing ~57% voting power executed written consent approving warrant share issuance.","Up to 34,767,934 shares of common stock may be issued under warrants to an institutional investor and H.C. Wainwright.","Issuance complies with Nasdaq Listing Rule 5635(d) for transactions exceeding 20% of outstanding shares.","Consent includes 6,552,781 common shares and 250,000 Class A Preferred shares (each with 285 votes).","Previously disclosed Inducement Letter (Oct 24, 2024) and Engagement Letter (Oct 23, 2024) are the basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176190,"accession_number":"0001104659-25-000343","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mustang Bio shareholders elect seven directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with at least 58.3M votes for each; broker non-votes none.","KPMG LLP ratified as independent auditor for FY 2024 with 59.4M for, 62.7K against, 30.6K abstain.","Approximately 58% of total votes were represented at the virtual annual meeting on Dec. 26, 2024.","Outstanding shares: 48.8M common, 0.8M Class A common, 0.25M Class A preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193090,"accession_number":"0001104659-24-119756","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Mustang Bio receives Nasdaq delist notice but granted extension; interim CFO resigns, CEO takes over","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Staff issued delist determination on Nov 13, 2024 for non-compliance with bid price rule.","Nasdaq Hearings Panel granted extension to Jan 31, 2025 for bid price and Feb 18, 2025 for equity rule compliance.","James Murphy resigned as Interim CFO on Nov 12, 2024; no disagreement involved.","President/CEO Manuel Litchman appointed Interim CFO effective Nov 15, 2024; previously held role in Dec 2023-Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193089,"accession_number":"0001104659-24-114835","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Mustang Bio schedules Dec 26, 2024 annual meeting; sets proposal deadlines Nov 16/18","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting set for December 26, 2024; time/location to be in proxy statement.","Rule 14a-8 proposals for proxy inclusion must be received by November 18, 2024.","Director nominations and non-14a-8 proposals must be submitted by November 16, 2024.","Universal proxy rule compliance also requires notice by November 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193088,"accession_number":"0001104659-24-111500","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Mustang Bio raises $4M via warrant exercise; appoints David Jin to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor exercised 16,877,638 existing warrants at $0.237/share for ~$4M gross proceeds, before fees.","Issued new unregistered warrants to purchase up to 33,755,276 shares at $0.27/share; exercisable after stockholder approval.","Board expanded to seven; David Jin (CFO of majority owner Fortress Biotech) appointed as director.","Net proceeds to be used for working capital and general corporate purposes.","H.C. Wainwright acted as placement agent with 7% cash fee and 1,012,658 placement agent warrants at $0.2963/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209466,"accession_number":"0001104659-24-099829","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Mustang Bio receives Nasdaq delisting notice for failure to meet equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff determined to delist MBIO due to non-compliance with $2.5M stockholders' equity requirement by Sept 9, 2024 extension deadline.","Company intends to request a hearing before Nasdaq Hearings Panel, which will stay delisting pending hearing and any granted extension.","Trading on Nasdaq Capital Market under symbol MBIO continues pending the hearing process.","No assurance that Panel will grant continued listing or that compliance can be shown within any extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209465,"accession_number":"0001104659-24-077596","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","1.02","2.01","5.07","9.01"],"status":"ready","headline":"Mustang Bio repurchases previously sold assets for $1.4M; shareholders approve reverse split and warrant share issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company to repurchase assets from uBriGene for $1,395,138; $100K upfront, $1,295,138 deferred for 12 months with possible extensions.","Shareholders approved issuance of up to 60,731,608 shares underlying warrants, representing over 20% of outstanding common stock.","Shareholders also authorized a reverse stock split between 1-for-10 and 1-for-50, with Board to determine exact ratio.","Repurchase is an Expedited Divestment under CFIUS National Security Agreement signed May 13, 2024, reversing the prior sale.","Company may defer deferred payment if net assets fall below $20M; unpaid amounts accrue 5% interest after 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227520,"accession_number":"0001104659-24-074043","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Mustang Bio raises $2.5M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,025,000 common shares and 3,105,000 pre-funded warrants (collectively 6,130,000 shares/equivalents) at $0.41/unit.","Concurrent private placement of 6,130,000 warrants with $0.41 exercise price, exercisable after stockholder approval for 5 years.","Gross proceeds ~$2.5M; net proceeds for working capital and general corporate purposes.","H.C. Wainwright as placement agent; paid 7% cash fee plus warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227519,"accession_number":"0001104659-24-069131","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Mustang Bio enters $5.6M ATM offering with H.C. Wainwright; terminates prior $100M agreement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["May 31, 2024: ATM Offering Agreement with H.C. Wainwright for up to $5.6M of common stock; 3.0% commission to manager.","Prior $100M ATM Sales Agreement with B. Riley Securities & others terminated effective June 5, 2024.","New S-3 registration statement (File No. 333-279891) filed same day enables the at-the-market offering.","Company not obligated to sell any shares; offering ends upon full sale or termination of agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227518,"accession_number":"0001558370-24-008535","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Mustang Bio receives second Nasdaq deficiency notice; stock bid below $1 for 31 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Mustang Bio on May 16, 2024 that bid price closed below $1 for 31 consecutive business days.","Company has 180 days, until November 12, 2024, to regain compliance by closing at $1.00 or more for 10+ days.","Prior stockholders' equity deficiency: Nasdaq granted extension through September 9, 2024 to regain compliance.","If not cured, Mustang may seek a second grace period or request a hearing to avoid delisting.","No decision yet on reverse stock split or other remedy; delisting risk remains if compliance is not achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227517,"accession_number":"0001104659-24-056459","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Mustang Bio closes $4M public offering of shares and warrants; amends existing warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4M from offering of shares and warrants at $0.237 per combined unit.","Net proceeds ~$3.3M; potential additional $12M if all series A-1, A-2, A-3 warrants cash-exercised.","Amended 2,588,236 existing warrants from $1.58 to $0.237 exercise price effective May 2.","Offering includes 16.9M shares and three series of warrants each for 16.9M shares.","H.C. Wainwright acted as placement agent; proceeds for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227516,"accession_number":"0001104659-24-053706","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Mustang Bio prelim Q1 cash $1.3M, operating burn $5.3M, cash runway concerns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and equivalents as of March 31, 2024: approximately $1.3 million.","Cash used in operating activities for Q1 2024: approximately $5.3 million.","Results are preliminary and subject to completion of closing procedures; actual results may differ.","Company cautions not to place undue reliance on these estimates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227515,"accession_number":"0001558370-24-005022","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Mustang Bio cuts workforce by 81% amid CFIUS uncertainty and facility sale to uBriGene","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved ~81% workforce reduction to reduce costs and preserve capital due to fundraising environment and CFIUS review of facility sale.","Workforce reduction expected substantially complete in Q2 2024; expects ~$0.2M in one-time termination cash expenditures.","Company continues to evaluate all strategic and other alternatives related to the business.","Sale of leasehold interest and assets to uBriGene (Chinese CDMO) pending CFIUS review; terms not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246358,"accession_number":"0001104659-24-041199","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mustang Bio provides CFIUS update on facility sale to uBriGene; investigation due by May 13, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Transaction involves sale of Worcester cell processing facility and manufacturing assets to uBriGene.","CFIUS review entered a second 45-day investigation period ending May 13, 2024.","CFIUS clearance not a condition to closing but may affect timing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246357,"accession_number":"0001104659-24-035016","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Mustang Bio receives Nasdaq delisting notice for equity shortfall; 45 days to submit compliance plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $123,000 falls short of Nasdaq's $2.5M minimum for continued listing.","Company has until April 29, 2024 to submit a plan to regain compliance.","If plan is accepted, Nasdaq may grant a 180-day extension; otherwise Company can appeal.","Trading continues on Nasdaq under MBIO with no immediate effect on listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246356,"accession_number":"0001104659-24-033015","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mustang Bio reports FY2023 net loss of $51.6M; cash drops to $7.0M; MB-106 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $7.0M at Dec 31, 2023, down from $76.7M at Dec 31, 2022; $30.4M debt termination payment in 2023.","Net loss $51.6M ($6.00/share) vs $77.5M ($10.09/share) in 2022; R&D spend $40.5M vs $62.5M.","MB-106 Phase 1/2 multicenter trial: 100% ORR in FL (n=5 all CR) and WM (n=3 with VGPR/PR); no severe CRS/ICANS.","Registrational trial in Waldenstrom macroglobulinemia planned H2 2024; topline expected H2 2026; RMAT designation request H1 2024.","Closed uBriGene asset sale for $6M upfront; $5M contingent; lease assignment subject to CFIUS review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246355,"accession_number":"0001104659-24-023665","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mustang Bio and uBriGene withdraw and re-file CFIUS notice; new 45-day review period begins Feb 13","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Feb 12, 2024, CFIUS granted request to withdraw and re-file the joint voluntary notice for the transaction.","New 45-day review period started Feb 13, 2024, concluding no later than March 28, 2024.","If CFIUS does not conclude by March 28, the proceeding will transition to a second 45-day investigation phase.","The CFIUS review relates to Mustang's sale of its Worcester cell processing facility and associated assets to uBriGene.","CFIUS clearance was not a condition to closing the transaction, but is being pursued voluntarily."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246354,"accession_number":"0001104659-24-006668","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mustang Bio appoints James Murphy as Interim CFO effective Jan 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Murphy appointed Interim CFO, serving as Principal Financial and Accounting Officer.","Murphy provides consulting services via Danforth Advisors; receives no direct compensation from Mustang.","Murphy has served as interim CFO for public and private life science companies since 2012.","No family relationships or material transactions exist between Murphy and Mustang's officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246353,"accession_number":"0001558370-24-000056","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mustang Bio CFIUS review for asset sale to uBrigene enters investigation phase; decision by Feb 12, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFIUS began a 45-day investigation after the initial review period expired on Dec 28, 2023 without conclusion.","CFIUS must complete its investigation no later than February 12, 2024.","Transaction involves sale of Mustang's Worcester cell processing facility and assets to uBrigene, a Chinese CDMO.","CFIUS clearance was not a condition to closing the transaction.","The parties previously withdrew and re-filed their CFIUS notice on Nov 13, 2023 to allow more review time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263799,"accession_number":"0001104659-23-125067","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mustang Bio Interim CFO Eliot Lurier passes away; CEO Litchman named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eliot Lurier, Interim CFO since April 2022, passed away unexpectedly on December 8, 2023.","Board appointed CEO Manuel Litchman, M.D. as Interim CFO, effective December 11, 2023.","Controller Peter Carney appointed Interim Chief Accounting Officer, also effective December 11, 2023.","No new compensation arrangements or employment agreements entered with Litchman or Carney.","Litchman has served as President & CEO since April 2017; Carney has been Controller since August 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263798,"accession_number":"0001558370-23-019708","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mustang Bio: MB-106 achieves 100% complete response in follicular lymphoma in Phase 1/2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% complete response rate in 5 follicular lymphoma patients; 100% overall response in follicular and Waldenstrom macroglobulinemia.","Favorable safety: no CRS > Grade 1, no ICANS; outpatient administration feasible.","Complete responses seen in patients previously treated with CD19-targeted CAR-T therapy.","Plan to finalize Phase 2 dose in early 2024; End-of-Phase 1 FDA meeting expected H1 2024.","Registrational trial planned for relapsed/refractory WM with 58 patients; top-line data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263797,"accession_number":"0001558370-23-019052","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mustang Bio Q3 net loss narrows to $10.1M; cash drops to $10.3M, raises $4.4M post-quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $10.3M at Sep 30, down from $16.1M at Jun 30 and $76.7M at Dec 31, 2022.","Net loss of $10.1M ($1.23/share) vs $19.0M ($2.42) in Q3 2022; R&D expenses fell to $9.5M.","CFIUS review of uBriGene asset sale restarted; new 45-day review period began Nov 14, lease transfer delayed.","MB-106 CAR-T showed 95% ORR in follicular lymphoma (n=20) and two complete responses in WM patients.","FDA accepted IND for MB-109 (MB-101 + MB-108) for recurrent glioblastoma; Phase 1 trial planned."],"consensus_eps_estimate":-65.025,"consensus_eps_actual":-5.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263796,"accession_number":"0001558370-23-017412","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mustang Bio's MB-106 CAR-T interim data selected for ASH; complete responses in FL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim Phase 1/2 data for MB-106 (CD20-targeted CAR-T) accepted as poster at ASH Dec 9-12, 2023.","At dose level 1 (3.3x10^6 cells/kg): two FL patients achieved complete response, WM patient VGPR, HCL-v stable disease with transfusion independence.","Safety: 3 patients Grade 1 CRS, no ICANS or dose-limiting toxicities; outpatient infusion allowed.","Patients heavily pre-treated (median 5.5 prior lines); WM patient had nine prior treatments including auto-SCT.","Pivotal Phase 2 WM trial expected to start mid-2024 with top-line data possible by mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263795,"accession_number":"0001104659-23-112515","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Mustang Bio raises ~$4.4M in registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.4M before fees; offering includes 2,588,236 shares (or equivalents) at $1.70 each.","Concurrent private placement of warrants to purchase 2,588,236 shares at $1.58, exercisable for 5.5 years.","Net proceeds to be used for working capital and general corporate purposes.","Placement agent H.C. Wainwright received 7.0% cash fee and 155,294 warrants exercisable at $2.125.","Offering closed on October 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263794,"accession_number":"0001558370-23-016852","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts IND for Mustang Bio's MB-109 combo therapy for recurrent glioblastoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IND accepted within 30 days of submission for MB-109 (MB-101 CAR-T + MB-108 oncolytic virus).","Phase 1 trial to start 2024; will test safety, tolerability, efficacy in recurrent GBM and high-grade astrocytoma.","Prior MB-101 alone saw complete responses lasting 7.5 and 31+ months in patients with hot tumors.","Study to enroll at City of Hope and University of Alabama at Birmingham.","Median overall survival for recurrent GBM is 6 months; combo aims to improve outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263793,"accession_number":"0001558370-23-016231","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CFIUS extends review of Mustang Bio facility sale to uBriGene into second 45-day phase","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CFIUS initial 45-day review completed Sep 28, 2023 but not concluded; transitions to second 45-day investigation.","CFIUS investigation to be completed no later than November 13, 2023.","Deal involves sale of Mustang's Worcester cell processing facility and manufacturing assets to uBriGene, a Chinese CDMO subsidiary.","CFIUS clearance was voluntarily submitted and not a condition to closing the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281009,"accession_number":"0001558370-23-015014","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mustang Bio reports 4 of 4 indolent lymphoma patients respond to MB-106 CAR T; dose escalation approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clinical responses in 4 of 4 indolent lymphoma patients at starting dose 3.3x10^6 CAR T cells/kg; 2 follicular lymphoma patients achieved CR.","Safety Review Committee unanimously approved dose escalation to 1.0x10^7 CAR T cells/kg; only Grade 1 CRS reported.","Fred Hutch trial (n=20 FL) shows 95% ORR, 80% CR; first patient sustained CR >3 years.","Waldenstrom macroglobulinemia cohort (n=6): 2 CR, one ongoing >22 months; no CRS/ICANS >Grade 2.","Pivotal Phase 2 for WM to start mid-2024, top-line data mid-2026; end-of-Phase 1 FDA meeting expected end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281008,"accession_number":"0001558370-23-014849","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mustang Bio Q2 net loss $16.2M; completes uBriGene asset sale for $6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $16.1M at June 30, down from $76.7M at Dec 31, 2022, reflecting Runway loan repayment.","Net loss $16.2M ($2.00/share) vs $19.1M ($2.50/share) in Q2 2022.","Closed amended asset sale to uBriGene for $6M upfront; expects $28M annual cost reduction.","Lead CAR T MB-106 shows 83% response in WM cohort; 95% ORR in FL cohort.","First pivotal Phase 2 WM patient expected Q1 2024; additional multicenter data in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281007,"accession_number":"0001558370-23-012508","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Mustang Bio closes amended asset sale to uBriGene for $6M upfront; cash runway into early 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed amended asset purchase agreement with uBriGene on July 28, 2023; received $6M upfront cash.","Additional $5M contingent payment requires Mustang to raise $10M+ equity and landlord consent for lease assignment.","Facility lease did not transfer; Mustang continues to occupy and manufacture MB-106; landlord has 30 days after CFIUS review.","If lease not transferred within 120 days, uBriGene can request repurchase negotiations of transferred assets.","Upfront proceeds and operating expense reductions extend cash runway into early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281006,"accession_number":"0001558370-23-012033","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Mustang Bio downsizes Worcester office; annual rent to drop from ~$583K to ~$246K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Relocation from 26,503 sq ft to 11,916 sq ft on second floor; rent abated until March 1, 2024.","New annual base rent of $246,312 for rest of 2023, escalating 2% yearly through Jan 2030.","Sublessor provides $119,160 tenant improvement allowance; must be used by Feb 29, 2024.","Company vacated existing premises with no holdover liability; not currently occupying any space."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281005,"accession_number":"0001104659-23-079819","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Mustang Bio terminates UCLA license for PSCA CAR T program, ends MB-105 development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated UCLA License Agreement for PSCA CAR T technology, effective ~Aug 9, 2023.","No early termination penalties incurred.","Previously terminated PSCA Technology License with City of Hope on May 17, 2023.","Licensed technology targeted prostate cancer, pancreatic cancer, and other solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299698,"accession_number":"0001558370-23-011634","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Mustang Bio extends asset sale deadline for Worcester facility to July 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mustang Bio and uBriGene amended Asset Purchase Agreement to extend Outside Date from June 30 to July 31, 2023.","Extension provides additional time to obtain landlord approval for site lease transition.","Parties may mutually extend in 30-day increments if only condition is landlord consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299697,"accession_number":"0001558370-23-011376","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Mustang Bio stockholders approve ESPP amendment increasing shares to 466,666","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved ESPP amendment increasing shares from 66,666 to 466,666 and purchase right to 5,000.","Six directors elected: Weiss, Rosenwald, Herskowitz, Litchman, Chill, Zelefsky (all >10.1M votes for).","KPMG ratified as independent auditor for FY2023 (13.4M for, 68K against).","Advisory say-on-pay passed (10.3M for); frequency of vote set at every 3 years (9.9M votes).","Approximately 87% of votes represented at the meeting, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299696,"accession_number":"0001558370-23-010276","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["1.01","1.02","2.05","8.01","9.01"],"status":"ready","headline":"Mustang Bio sells facility to uBriGene for up to $11M, discontinues four CAR T programs, cuts 82% workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sells Worcester cell processing facility to uBriGene for $6M upfront plus $5M contingent on $10M equity raise.","Discontinues MB-102 (CD123), MB-103 (HER2), MB-104 (CS1), MB-105 (PSCA) programs; terminates City of Hope licenses.","Workforce reduction of ~82% (inclusive of offered employees); expects $2.9M severance costs and $24M annualized savings.","XSCID gene therapy program enrollment paused; awaiting data from modified vector trials; no safety concerns noted.","Enters manufacturing services agreement with uBriGene; commits to at least $8M spend over two years for MB-106 and future pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299695,"accession_number":"0001558370-23-009622","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mustang Bio Q1 net loss $16.7M, cash $58.8M; MB-106 trial data expected Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $58.8M at Mar 31, 2023, down $17.9M from Dec 31, 2022.","Net loss $16.7M ($2.06/share) vs $19.8M ($2.71/share) in Q1 2022; R&D expenses $14.0M.","MB-106 (CD20 CAR T) shows 96% ORR and 75% CR in Fred Hutch trial; multicenter trial accruing.","Orphan Drug Designation for MB-106 in Waldenstrom macroglobulinemia; pivotal Phase 2 may start Q1 2024.","In April 2023, executed 15-for-1 reverse stock split and repaid $30.7M loan to Runway."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299694,"accession_number":"0001558370-23-006343","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mustang Bio amends ATM equity program; up to $100M authorized, ~$8M remaining","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment No. 3 to At Market Issuance Sales Agreement dated April 14, 2023.","Total ATM offering capacity remains $100M; ~$92M already sold, ~$8M available.","Adds Instruction I.B.6 limitations based on non-affiliate market cap; removes Oppenheimer & Co. as agent.","No securities sold under Instruction I.B.6 in prior 12 months; program continues under existing registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299693,"accession_number":"0001104659-23-044767","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Mustang Bio terminates $75M Runway loan, pays $30.7M payoff","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Runway Loan Agreement (March 4, 2022) on April 11, 2023.","Company paid $30.7M to Runway Growth Finance Corp. covering principal, interest, and final payment.","Original facility provided up to $75M in term loans subject to milestone achievements.","Certain indemnification obligations under Section 12.3 survive termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299692,"accession_number":"0001558370-23-005369","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Mustang Bio effects 15-for-1 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective April 3, 2023; shares trade split-adjusted April 4.","Outstanding shares reduced from ~109.4M to ~7.3M; no fractional shares issued.","Split approved by ~62.2% of voting power; Board set ratio on March 15.","Aimed at meeting Nasdaq $1.00 minimum bid price requirement for continued listing.","Bylaws amended to change quorum requirement to majority of outstanding voting power."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319804,"accession_number":"0001558370-23-004930","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mustang Bio reports FY2022 net loss $77.5M; MB-106 shows 96% ORR, 75% CR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $76.7M at Dec 31, 2022, down from $110.6M year-over-year.","Net loss $77.5M ($0.75/share) vs $66.4M ($0.76/share) in 2021; R&D expenses rose to $62.5M.","MB-106 CAR T therapy achieved 96% ORR and 75% CR in hematologic malignancies; FDA Orphan Drug Designation for Waldenstrom macroglobulinemia.","Completed $75M debt financing with Runway Growth Capital; $30M funded at close, $45M milestone-based.","Plans to treat first pivotal Phase 2 WM patient in Q1 2024; additional data expected in Q2 and Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319803,"accession_number":"0001558370-23-002778","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mustang Bio shareholders authorize board to effect reverse stock split up to 20:1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of ~62.2% voting power signed written consent approving reverse stock split.","Board authorized to set ratio between 5:1 and 20:1, with split to occur before Jan 31, 2024.","Consent signed by holders of 22,630,620 common shares and 250,000 Class A Preferred shares.","Board also approved the reverse stock split and amendment to certificate of incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338020,"accession_number":"0001558370-22-018593","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Mustang Bio amends $75M loan agreement to replace LIBOR with SOFR-based rates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First Amendment to $75M Loan Agreement with Runway Growth Finance Corp., dated Dec 7, 2022.","Replaces LIBOR with Adjusted Term SOFR Rate (Term SOFR + 0.26%, floor 0.50%).","Applicable Margin of 8.75% when using Adjusted Term SOFR Rate; total rate floor of 9.25%.","Amendment includes fallback provisions if SOFR unavailable (Prime Rate alternative).","No change to principal amount or maturity; loan terms otherwise unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-12-13T23:59:59+00:00|338020"}